ProspeCtive Study to Evaluate Efficacy, Safety and tOlerability of Dietary supplemeNT of Curcumin (BCM95) in Subjects With Active Relapsing MultIple Sclerosis Treated With subcutaNeous Interferon Beta 1a 44 Mcg Three Times a Week (TIW).
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Curcumin; Interferon beta-1a
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms CONTAIN
- 22 Jan 2019 Biomarkers information updated
- 02 Oct 2012 Planned End Date changed from 1 Aug 2015 to 1 Oct 2014 as reported by ClinicalTrials.gov record.
- 27 Jan 2012 New trial record